Compared to other drugs commonly used for allergy, ibrutinib and acalabrutinib offer several unique benefits, including the ability to effectively inhibit IgE-FcεRI-mediated activation of both mast cells and basophils, rapid onset of action and transient efficacy (59, 128). The gene discussed is IGHE; the disease is allergic disease.